Ipilimumab
CA184-024
Phase 3 small_molecule completed
Quick answer
Ipilimumab for Melanoma is a Phase 3 program (small_molecule) at Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb
- Indication
- Melanoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed